Curated News
By: NewsRamp Editorial Staff
June 29, 2026

NeuroOne Joins Russell Microcap® Index, Boosting Investor Visibility

Discuss on Substack
Original Source

TLDR

  • NeuroOne's inclusion in Russell Microcap Index boosts visibility among institutional investors, potentially increasing stock liquidity and demand.
  • FTSE Russell adds NeuroOne to Microcap Index based on market cap rankings; inclusion triggers automatic placement in related indexes for six months.
  • NeuroOne's electrode technology improves brain surgery outcomes, reducing hospitalizations and costs, making neurological care more accessible and effective.
  • NeuroOne's FDA-cleared products include a trigeminal nerve ablation system for treating facial pain, a novel minimally invasive solution.

Impact - Why it Matters

This inclusion matters because being part of a widely-followed index like the Russell Microcap® can increase NeuroOne's visibility among institutional investors and index funds, potentially leading to greater liquidity and stock price stability. For investors, this signals that the company meets objective market-capitalization criteria, validating its growth trajectory. For patients and healthcare providers, NeuroOne's focus on minimally invasive neurological solutions could mean fewer surgeries and better outcomes, making this index addition a reflection of its potential to transform neurological care.

Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has been added to the Russell Microcap® Index, effective with the US market open on June 29, 2026, as part of the annual Russell indexes reconstitution. This inclusion places NeuroOne among the smallest 1,000 securities in the Russell 2000® Index plus the next 1,000 smallest eligible securities, reflecting the company's growing market presence. The Russell indexes, managed by FTSE Russell, are widely used by investment managers and institutional investors, with approximately $12.2 trillion in assets benchmarked against them as of June 2025. This milestone could enhance NeuroOne's visibility among investors and potentially attract index fund investments.

NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. The company markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. Additionally, NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more details, visit nmtc1.com.

Inclusion in the Russell Microcap® Index is a significant achievement for NeuroOne, as it provides broader exposure to the investment community. According to data from FTSE Russell, the Russell indexes are a key benchmark for active investment strategies. The company's addition to the index underscores its progress in the medical technology sector. Investors can find more information on the Russell reconstitution on the FTSE Russell website. The original announcement was distributed via NEWMEDIAWIRE.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Joins Russell Microcap® Index, Boosting Investor Visibility

blockchain registration record for this content.